6-K ·Filed Mar 26, 2026

GSK

GSK plc
NEUTRAL
Impact 3/10
Horizonimmediate Processed6mo ago SEC0001654954-26-002780
Notable filing: 6-K
Actionable Insight • Neutral

Monitor future buyback activity and total program size; assess impact on EPS and capital allocation strategy. Consider potential signal of management confidence, but note this is a routine program execution.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
GSK ▼ -4.17% at T+60d
NEUTRAL call ✗ call lost -4.17% · α vs SPY -18.12% · entry $53.94 → $51.69
Entry anchored
Mar 25, 03:59 PM ET
via exchange tick
T+1d
-0.19%
call -0.19% · α +1.49%
$53.84
settled 6mo ago
T+5d
+5.10%
call +5.10% · α +3.46%
$56.69
settled 6mo ago
T+20d
+0.93%
call +0.93% · α -9.74%
$54.44
settled 5mo ago
T+60d
-4.17%
call -4.17% · α -18.12%
$51.69
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

GSK plc announced the purchase of 345,000 of its ordinary shares on 25 March 2026 at a volume-weighted average price of 2,033.20 GBp per share, as part of its ongoing buyback program. Since 17 February 2026, the company has bought back 14,856,521 shares. The shares were acquired through BNP Paribas SA and will be held as treasury shares.

Key Facts

  • GSK purchased 345,000 ordinary shares on 25 March 2026
  • Volume-weighted average price paid: 2,033.20 GBp per share
  • Shares were acquired via BNP Paribas SA as part of a non-discretionary buyback program
  • Since 17 February 2026, GSK has bought back 14,856,521 shares
  • Purchased shares will be held as treasury shares

Financial Impact

Total cost of 345,000 shares at 2,033.20 GBp is approximately £7.01 million (based on GBP/USD exchange rate of 1.28, ~$9.0 million)

shares outstandingcash flow

Risk Factors

  • Buybacks reduce cash reserves and may signal limited growth investment opportunities
  • If buybacks continue at elevated pace, could constrain future R&D or M&A capacity

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-002780
Document: 0001654954-26-002780-index-headers.html0001654954-26-002780
Document: 0001654954-26-002780-index.html0001654954-26-002780
Document: 0001654954-26-002780.txt0001654954-26-002780
42 reports for GSK
Performance horizon
69% Hit rate 11 of 16 directional calls best @ T+60▲ +7.85%Jun 16, 2026
Filters
Rows
Reports for GSK — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
6-K
NEUTRAL ★ 5/10
$50.01 $50.22▲ +0.42%▼ −0.40%$47.01 (−5.99%)
Sep 14, 2026
18d ago
6-K
BULLISH ★ 7/10
$50.05 $51.08▲ +2.06%▲ +1.95%$47.01 (−6.06%)
Sep 14, 2026
18d ago
6-K
BULLISH ★ 7/10
$50.05 $51.08▲ +2.06%▲ +1.95%$47.01 (−6.06%)
Sep 11, 2026
21d ago
6-K
NEUTRAL ★ 1/10
$48.13 $50.22▲ +4.34%▲ +4.56%$47.01 (−2.32%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 1/10
$48.12 $51.06▲ +6.11%▲ +6.61%$47.01 (−2.30%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 3/10
$48.12 $51.06▲ +6.11%▲ +6.61%$47.01 (−2.30%)
Sep 1, 2026
4w ago
6-K
NEUTRAL ★ 1/10
$50.66 $48.63▼ −4.01%▼ −4.09%$47.01 (−7.20%)
Sep 1, 2026
4w ago
6-K
BULLISH ★ 6/10
$50.66 $48.63▼ −4.01%▼ −4.09%$47.01 (−7.20%)
Aug 26, 2026
5w ago
6-K
NEUTRAL ★ 1/10
$51.43 $50.44▼ −1.92%▼ −1.80%$47.01 (−8.58%)
Aug 24, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$51.78 $50.25▼ −2.95%▼ −3.42%$47.01 (−9.20%)
Showing 10 of 42

US Market Status

Market Open — Closes in 1h 11m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access